The Actuarial Profession: Mortality and Longevity 15th April 2008

What might the future hold? The ageing process and the prospects for prolonging life expectancy



David Gems University College London david.gems@ucl.ac.uk

Institute of Healthy Ageing

Today's talk

Introduction to biogerontology
Goals of research on ageing
The new genetics of ageing
Prospects for treatments for ageing

What is Biogerontology?





10 questions about ageing

1) Comparative biology: How does ageing and longevity vary between species? Are there non-ageing organisms?









- genome, and if so how?4) Model organisms: Can aging be suppressed and lifespan
- increased?





- 5) Molecular biology/ biochemistry: What is the basis of ageing and longevity?
- 6) Cell biology: How does cellular senescence contribute to ageing and cancer? How are telomeres important?
- 7) Gerontology: How does ageing give rise to ageing-related disease?
- 8) Immunology: Why does the immune system fail in ageing? How does this impact health in later life?

Future prospect and bioethics

- 9) What are the prospects for treatments for ageing?
- 10) What should the aims of ageing research be? Is ageing a disease?



What is biogerontology for?



We are living longer



Mme. Jeanne Calment Born February 1875 Died August 1997, aged 122 years

Living longer has a downside



Alzheimer's disease

Iris Murdoch

Ageing-related pathologies are very diverse

Cardiovascular, eg. atherosclerosis, arteriosclerosis, hypertension, valvular fibrosis and calcification Central nervous, eg. *B*-amyloid depositions, neuritic plaques, neurofibrillary tangles and others leading to Parkinson's and Alzheimer's diseases Gastrointestinal, eg. colonic polyps, diverticulosis of colon Haematopoietic, eg. anaemias, chronic lymphocytic leukaemia Integumentary, eg. senile keratoses, epidermal atrophy Musculoskeletal, eg. skeletal muscle atrophy, osteoporosis, osteoarthritis Special senses, eg. cataracts, macular degeneration, loss of high frequency auditory and olfactory acuity Endocrine, eg. non-insulin-dependent diabetes mellitus. Epithelia. eg. carcinomas Peripheral nervous, e.g. segmental demyelination

George Martin, Senescence and health in old age

The Biology of Ageing

Ageing → **Disease**

Treatments for age-related diseases Current strategy

rch '

irch

Cancer	Cancer resea
Cardiovascular disease —	CV research
Alzheimer disease	AD research
Parkinson disease	PD research
Macular degeneration -	AMD resear
Type II diabetes	Diabetes rese
Osteonorosis	Bone researc

Treatment for cancer Treatment for CV disease Treatment for AD Treatment for PD Treatment for AMD Treatment for diabetes Treatment for OP



Protection against age-related disease in rodents by dietary restriction

- •Autoimmune disorders
- •Cancer (breast, prostate, immune system and GI tract)
- •Cataracts
- •Type II diabetes
- •Hypertension
- •Kidney failure



Treating Diseases of Ageing



Understand the Biology of Ageing Institute of Healthy Ageing

The New Genetics of Ageing

What is ageing?



Genes control ageing

Understanding Lifespan: The Classical Genetic Approach

•Isolate mutants with altered rates of ageing
•Map, clone and sequence genes concerned
•Identify lifespan-determining proteins, biochemistry, etc
•Understand ageing?

C. elegans



Lifespan 2-3 weeks











Understanding Lifespan: The Classical Genetic Approach

•Isolate mutants with altered rates of ageing
•Map, clone and sequence genes concerned
•Identify lifespan-determining proteins, biochemistry, etc
•Understand ageing?











The Prospects for Treatments for Ageing







Developments within Biogerontology

1983: First long lived *C. elegans* mutant described 1996: First long-lived mouse mutant, first longevity genes sequenced in *C. elegans* 2001: Long-lived insulin/IGF-1 mutant fruitflies 2003: Long-lived insulin/IGF-1 mutant mice 2005: Drugs extending lifespan in *C. elegans* 2008: 10-fold increase of lifespan in *C. elegans*

Rapid progress in biogerontology

Proven treatments for human ageing derived from biogerontology



Average life expectancy likely to decrease due to epidemic of obesity



The Future

•Effective treatments for ageing are not imminent

The genetics of ageing is rapidly identifying potential drug targets
The fundamental biology of ageing is likely to be solved at some point
Treatments for ageing are very likely to

be devised at some point

•When, what level of efficacy?



Bacterial pathogens

Antibiotics = broad

spectrum treatment

Magic bullet



Cancer

Chemotherapy

Radiotherapy

Surgery

No magic

bullet

A magic bullet for ageing?

Ageing Mechanism unknown (accumulation o

(accumulation of molecular damage)

Magic bullet unlikely?

Looking into the future



2008-2020: Drugs targeting longevity control pathways identified and proven effective in nematodes, fruitflies and mice 2013-2030: First successful human trials, show reduction in agerelated pathology at advanced ages However: effects are small (+1-3 yrs) relative to benefits e.g. of exercise, controlled diet, social engagement 2008-2025: Underlying biology of ageing is understood 2015-2040: More powerful treatments from full understanding of ageing, effective in nematodes, fruitflies and mice 2020-2050: First successful human trials, substantial effects,

Is, show reduction in ageelative to benefits e.g. of ment ng is understood from full understanding of es and mice

2015-2040: More powerful treatments from full understanding of ageing, effective in nematodes, fruitflies and mice 2020-2050: First successful human trials, substantial effects, initially +2-5 years, but increasing decade by decade





